Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adze1.C in Metastatic Melanoma
NCT07086105Phase 1Recruiting
- Sponsor
- Adze Biotechnology
- Start
- Oct 2025
- Primary completion
- Oct 2027
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Adze1.C in melanoma, sponsored by Adze Biotechnology. Primary endpoints: Incidence and severity of treatment-emergent adverse events at 16 weeks and Incidence of dose-limiting toxicities at 5 weeks. Started Oct 2025; status: recruiting.
02
Drugs
Adze1.C
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT07086105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07086105.